Arena Pharmaceuticals Reports Topline Results from Phase 2b CAPTIVATE Clinical Trial
Details : The results show that, although olorinab was well tolerated, it did not meet the primary efficacy endpoint of statistically significant improvement in the overall AAPS from baseline to week 12.
Product Name : APD371
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
February 03, 2021
Details : Arena is evaluating 3 doses of olorinab in study participants with the clinical diagnosis of irritable bowel syndrome with predominant constipation (IBS-C) or diarrhea (IBS-D).
Product Name : APD371
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
January 10, 2020
Reset All
